May 26, 2026Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 5, 2026Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Apr 21, 2026Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
Feb 25, 2026Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Feb 23, 2026Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Feb 11, 2026Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
Jan 7, 2026Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Dec 12, 2025Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
